Susquehanna International Group’s Apogee Therapeutics APGE Stock Holding History

Susquehanna International Group’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.1M	Buy	190,800 +111,400	+140%	+$8.09M	﹤0.01%	2485
2025 Q4	$5.99M	Buy	79,400 +40,400	+104%	+$2.54M	﹤0.01%	3741
2025 Q3	$1.55M	Sell	39,000 -79,900	-67%	-$3.05M	﹤0.01%	6341
2025 Q2	$5.16M	Buy	118,900 +34,300	+41%	+$1.3M	﹤0.01%	3907
2025 Q1	$3.16M	Buy	+84,600	New	+$3.27M	﹤0.01%	4554
2024 Q4	–	Sell	-6,600	Closed	-$388K	–	12124
2024 Q3	$388K	Buy	+6,600	New	+$316K	﹤0.01%	9061
2024 Q2	–	Sell	-17,700	Closed	-$1.18M	–	11979
2024 Q1	$1.18M	Buy	+17,700	New	+$773K	﹤0.01%	6495

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Susquehanna International Group's APGE Position: Q1 2026 in Review

Susquehanna International Group increased its Apogee Therapeutics (APGE) stake by 247% in Q1 2026, buying an estimated $833K and bringing the position to 16,099 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #7143.

Susquehanna International Group first reported a position in APGE in Q4 2023 and has held it in 10 quarters since. The position peaked at $3.03M in Q3 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Susquehanna International Group held 16,099 shares of Apogee Therapeutics worth $1.36M as of Q1 2026.
Susquehanna International Group bought 11,465 Apogee Therapeutics shares in Q1 2026, an estimated $833K.
Apogee Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7143 holding.
Susquehanna International Group first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 10 quarters since.
Susquehanna International Group's Apogee Therapeutics position peaked at $3.03M in Q3 2024.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.